Bach / Good Clinical Immunobiology

1. Auflage 2014
ISBN: 978-1-4832-1634-8
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 3, 462 Seiten, Web PDF

Reihe: Clinical Immunobiology

Clinical Immunobiology, Volume 3 covers a variety of methods used for assaying the immune status of an individual. This volume is composed of 21 chapters and begins with a presentation of the background and issues to which clinical tests would be applied. The succeeding chapters outline the methodological procedures used in the analyses. Other chapters present some examples of the kinds of data that can be generated with the procedures used and provide guidelines for interpretation of the tests. The remaining chapters discuss the value of the immunological test procedures in differential diagnosis and analysis of diseases. These chapters also explore the usefulness of these procedures in prognosis of disease and the consequences of immunological manipulation undertaken for treatment or prevention of disease. This book will be of great value to clinical immunobiologists, biochemists, and researchers.

Autoren/Hrsg.

Bach, Fritz H.

Good, Robert A.

Inhaltsverzeichnis

1;Front Cover;1
2;Clinical Immunobiology;4
3;Copyright Page;5
4;Table of Contents;6
5;List of Contributors;12
6;Preface;16
7;Contents of Previous Volumes;20
8;Chapter 1. Evaluation of the Immunoglobulins;22
8.1;I. Introduction;22
8.2;II. Techniques;23
8.3;III. Results;32
8.4;IV. Summary;40
8.5;References;40
9;Chapter 2. Electrophoresis and Immunoelectrophoresis in the Evaluation of Homogeneous Immunoglobulin Components;42
9.1;I. Introduction;42
9.2;II. Homogeneous Proteins in Disease States;44
9.3;III. Techniques for Characterization and Quantitation of Homogeneous Immunoglobulin Components;48
9.4;IV. Evaluation of Test Results;51
9.5;V. Conclusions;56
9.6;References;57
10;Chapter 3. Serum Concentrations of IgG Subclasses;58
10.1;I. Introduction;58
10.2;II. Quantitative Determination of IgG Subclasses;61
10.3;III. IgG Subclass Concentrations in Sera of Normal Individuals;62
10.4;IV. Subclass Levels in Sera of Patients with Increased Concentrations of Total IgG;68
10.5;V. IgG Subclasses in Primary Immunodeficiency Diseases;71
10.6;VI. IgG Subclasses after Bone Marrow Transplantation in Severe Combined Immunodeficiency;73
10.7;Acknowledgments;76
10.8;References;76
11;Chapter 4. Imbalances of the k/. Ratio of Human Immunoglobulins;78
11.1;I. Introduction;78
11.2;II. Methods for Detection of Human Immunoglobulin Light-Chain Imbalances;80
11.3;III. Analyses of Normal and Pathological Sera;83
11.4;IV. Conclusions;89
11.5;References;90
12;Chapter 5. Metabolism of Immunoglobulins;92
12.1;I. Introduction;92
12.2;II. Methods Used in Immunoglobulin Turnover Studies;94
12.3;III. Metabolism of Immunoglobulins in Normal Individuals;97
12.4;IV. Problems in Interpretation of the Data;99
12.5;V. Disorders of Immunoglobulin Metabolism;100
12.6;VI. Summary;113
12.7;References;114
13;Chapter 6. Cell-Mediated Immunity: In Vivo Testing;118
13.1;I. Introduction;118
13.2;II. Skin Test Battery;120
13.3;III. Results;122
13.4;IV. Differential Diagnosis;124
13.5;References;125
14;Chapter 7. Cellular Immunity: Antibody-Dependent Cytotoxicity (K-Cell Activity);128
14.1;I. Introduction;128
14.2;II. Model Studies with Effector Cells from Nonimmune Donors;129
14.3;III. K-Cell Activity in Different Immune Systems;142
14.4;References;151
15;Chapter 8. Short-Term 51Cr-Release Tests for Direct Cell-Mediated Cytotoxicity: Methods, Clinical Uses, and Interpretations;154
15.1;I. Introduction;154
15.2;II. Pathways for Direct Cell-Mediated Cytotoxicity;155
15.3;III. Methodology;156
15.4;IV. Examples of Clinical Applications;159
15.5;V. Interpretive Limitations;161
15.6;VI. Some Future Applications;165
15.7;VII. Concluding Comments;166
15.8;Acknowledgments;167
15.9;References;167
16;Chapter 9. Lymphocyte Transformation in Vitro in Response to Mitogens and Antigens;172
16.1;I. Introduction;173
16.2;II. Lymphocyte Activation: Specific or Nonspecific;174
16.3;III. Characteristics of the Reaction;180
16.4;IV. Regulation of the Reaction;188
16.5;V. Lymphocyte Transformation in Vitro in Clinical Immunology;195
16.6;References;211
17;Chapter 10. Products of Activated Lymphocytes;216
17.1;I. Introduction;216
17.2;II. Cell Migration Inhibition System;217
17.3;III. Macrophage Activation by Lymphocyte Mediators;226
17.4;IV. Macrophage (Monocyte) Chemotactic Factor;230
17.5;V. Lymphocyte Mitogenic ( Blastogenic ) Factors;233
17.6;VI. Cytotoxic Factors ( Lymphotoxins );235
17.7;VII. Interferon;238
17.8;VIII. Summary;240
17.9;References;240
18;Chapter 11. Leukocyte Aggregation Test for Evaluating Cell-Mediated Immunity;242
18.1;I. Introduction;242
18.2;II. Method;244
18.3;III. Results;250
18.4;IV. Discussion;253
18.5;Acknowledgments;256
18.6;References;256
19;Chapter 12. The HLA System: Serologically Defined Antigens;258
19.1;I. The HLA System: Serologically Defined Antigens;258
19.2;II. HLA and Transplantation;272
19.3;III. HLA and Disease;273
19.4;IV. Clinical Applications;280
19.5;References;281
20;Chapter 13. Mixed Leukocyte Cultures: A Cellular Approach to Histocompatibility Testing;294
20.1;I. Introduction;294
20.2;II. Methods;297
20.3;III. Results;299
20.4;IV. Clinical Usefulness of Mixed Leukocyte Culture Testing;307
20.5;V. Addendum;308
20.6;References;308
21;Chapter 14. The Reticuloendothelial System;310
21.1;I. Introduction;310
21.2;II. Clearance Testing;311
21.3;III. Rebuck Skin Windows;316
21.4;IV. Cellular Studies;317
21.5;References;323
22;Chapter 15. Assessment of Allergic States: IgE Methodology and the Measurement of Allergen-Specific IgG Antibody;326
22.1;I. Introduction;326
22.2;II. Total Serum IgE;327
22.3;III. Allergen-Specific IgE;334
22.4;IV. Allergen-Specific IgG Antibodies;357
22.5;V. Conclusions;364
22.6;Selected References;365
23;Chapter 16. Autoantibodies in Hematological Disorders;366
23.1;I. Introduction;366
23.2;II. Autoimmune Hemolytic Anemia;367
23.3;III. Autoantibodies against Thrombocytes;376
23.4;IV. Autoantibodies against Leukocytes;380
23.5;Appendix;382
23.6;References;385
24;Chapter 17. Rheumatoid Factors in Human Disease;386
24.1;I. Introduction;386
24.2;II. General Test Procedures;387
24.3;III. Clinical Significance;388
24.4;Appendix: Commonly Used Rheumatoid Factor Tests;392
24.5;References;394
25;Chapter 18. Antibodies to Nucleic Acids;396
25.1;I. Introduction;396
25.2;II. Performance of the Tests;399
25.3;III. Results and Interpretation;401
25.4;IV. Differential Diagnosis;404
25.5;References;406
26;Chapter 19. Complement;408
26.1;I. Introduction;408
26.2;II. Complement Components and Activation Sequence;409
26.3;III. Biological Activities of Complement;412
26.4;IV. Tests Involving Complement;413
26.5;V. Complement-Fixation Tests;418
26.6;VI. Miscellaneous Tests;418
26.7;VII. Complement Abnormalities in Disease;419
26.8;VIII. Inherited Disorders of the Complement System;421
26.9;References;424
27;Chapter 20. Detection of Tumor-Associated Antigens in Plasma or Serum;426
27.1;I. Introduction;426
27.2;II. a-Fetoprotein;427
27.3;III. Carcinoembryonic Antigen;434
27.4;IV. Other Antigens, Antibodies;441
27.5;V. Conclusion;444
27.6;References;445
28;Chapter 21. Neutrophil Function;448
28.1;I. Introduction;448
28.2;II. Phagocytosis;450
28.3;III. Bactericidal Assays of Neutrophils;453
28.4;IV. Assays of Neutrophil Movement;455
28.5;References;458
29;Subject Index;460